BioSpace News Archive

Surmodics, Inc. today announced that 24-month data from its TRANSCEND clinical trial has been presented at the Vascular InterVentional Advances (VIVA) annual conference in Las Vegas.

Simulations Plus, Inc today announced that, through a joint proposal with the University of Florida’s College of Pharmacy it has been awarded a new funded contract from the U.S. Food and Drug Administration (FDA) to advance in vitro and (patho)physiology-based pharmacokinetics (PBPK) models to understand and predict pulmonary absorption and tissue retention of inhaled drugs.

BiomX Inc. (NYSE American) today announced that the Company will host a conference call and a live audio webcast on Wednesday, November 9, 2022, at 8:00 a.m. ET, to report third quarter 2022 financial results and provide business updates.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of an interim analysis of the Phase 4 REFINE-ALS study, designed to identify predictive and pharmacodynamic biomarkers to measure the effect of RADICAVA® (edaravone) in people with amyotrophic lateral sclerosis (ALS).

CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and inflammatory diseases, announces it has secured $9.2m to progress the company’s lead oncology asset CV6-168 into a first-in-human Phase 1a clinical trial and perform further scientific development work.

Anavasi Diagnostics (‘Anavasi’), an NIH/RADx medical technology company focused on the development of novel molecular diagnostic testing, recently announced the election of three new outside members to its Board of Directors, Bryan Crane, PhD, Arthur Kirsch, and David Vied.

Blu Biotech Inc. entered into a Patent License Agreement with Innovation Partnerships at the University of Michigan (U-M) to develop and commercialize a Micro Gas Chromatography Photoionization Detector (Micro-GC-PID).

Ceruvia Lifesciences, a leading neurotransformational biopharmaceutical company, is pleased to announce the appointment of Stephen Hurst and David Steinberg to its Board of Directors, effective immediately.

According to Nova one advisor, the global Pressure Ulcers Treatment market was valued at USD 5.9 billion in 2021 and it is expected to hit around USD 11.2 billion by 2030 with a CAGR of 5.10% during the forecast period 2022 to 2030.

According to Nova one advisor, the global Glioma Treatment market size is expected to hit around USD 7.55 billion by 2030 from valued at USD 4.59 billion in 2021 and growing at a CAGR of 5.14% from 2022 to 2030.